Natera said that this research collaboration and others will help it clinically validate its circulating tumor DNA assay Signatera.
The Index gained 4 percent, outperforming the Dow and the Nasdaq, but underperformed the Nasdaq Biotechnology Index, which rose 5 percent.
Natera has entered the oncology space with a ctDNA assay and sees its blood banking service as a way to eventually tap into the consumer genomics space.
Natera ran 17 percent more tests in Q2 than it did in the prior-year period, generating $53.6 million in total revenues.
The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.
In a revised medical policy, Aetna said it would continue to cover NIPT for high-risk pregnancies, but not average-risk ones.
Counsyl believes its data is robust, while Natera has called the methodology and conclusions "gratuitously wrong." Both published opposing response letters this week.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
Natera said that the new product would further establish the company as a one-stop shop in the reproductive health market from pre-pregnancy through birth.
Natera's testing volumes increased but revenues declined due to achieving in-network status with payors and being reimbursed at a lower rate.
Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.
In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.
The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.
Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.